

## ABOUT TIGENIX

Advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions.

Lead product, Cx601, filed for EMA registration for the treatment of a severe, debilitating complication of Crohn's disease. Partnered ex-US with Takeda Pharmaceuticals.

Strong pipeline in inflammatory, autoimmune and cardiac diseases.

## QUICK FACTS

**Website:** www.tigenix.com  
**Ticker symbol:** TIG (Euronext & NASDAQ)  
**Headquarters:** Leuven, Belgium  
**Number of employees:** > 100

## UPCOMING MILESTONES

- EMA decision on Cx601 EU approval (H2 2017)
- Plan on new indications for Cx601
- Cx601 IND and start of recruitment in US centers

## MANAGEMENT

- CEO: **Eduardo Bravo**
- CFO: **Dr. Claudia D'Augusta**
- CTO: **Dr. Wilfried Dalemans**
- CMO: **Dr. Marie Paule Richard**
- VP Regulatory Affairs and Corporate Quality: **Dr. Maria Pascual**
- VP Medical Affairs and Commercialization: **Dr. Mary Carmen Diez**
- Director of Human Resources: **Susana Rojo**

## TECHNOLOGY AND PIPELINE

Two proprietary platforms of expanded allogeneic stem cells:

- Expanded adipose-derived stem cells (eASCs)
- Cardiac stem cells (CSCs)

**Product candidates:**

- **Cx601: locally administered** eASCs for the treatment of **complex perianal fistulas in Crohn's disease patients**. Filed for EMA registration in Q1 2016; Global pivotal phase III trial targeting BLA filing in the US started in H1 2017; **Partnered ex-US with Takeda Pharmaceuticals**.
- **Cx611: Systemic** (IV) administration of eASCs for the treatment of **autoimmune diseases**. Cx611 is currently being evaluated in a **Phase I/II trial in severe sepsis** (the SEPCELL study).
- **AlloCSC-01: Intracoronary administration** of CSCs for the treatment of acute ischemic heart disease. 1 year data from **CAREMI Phase I/II study** demonstrated **safety in acute myocardial infarction** (AMI) and reduction in infarct size in a subset of patients with a large MI and poor prognosis.

	Product	Indication	Preclinic	Phase I	Phase II	Phase III	Registration / Market
Allogeneic Adipose-Derived Stem Cells	Cx601 (EU)	Complex Perianal Fistulas in Crohn's disease*	Partnered; CHMP opinion expected 2H 2017				
	Cx601 (USA)	Complex Perianal Fistulas in Crohn's disease	Global Phase III for BLA started 1H2017				
	Cx611 (intravenous)	Severe Sepsis					
Allogeneic Cardiac Stem Cells	AlloCSC-01 (intracoronary)	Acute Myocardial Infarction					